Northwest Biotherapeutics (OTCMKTS:NWBO) is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of solid tumor cancers. Founded in 1996 and headquartered in Bethesda, Maryland, the company is dedicated to harnessing the body’s own immune system to target and destroy cancer cells, with an emphasis on improving survival and quality of life for patients worldwide.
The company’s lead product candidates are based on the DCVax platform, which uses patient-derived dendritic cells to present tumor-specific antigens and elicit a targeted immune response. DCVax-L is being investigated for newly diagnosed and recurrent glioblastoma multiforme (GBM), with late-stage trials conducted across multiple sites in the United States, United Kingdom, and Germany. In parallel, DCVax-Direct is being evaluated in a broad array of solid tumor settings through flexible trial designs that allow for intratumoral administration. Additional programs, such as DCVax-Prostate, explore applications in other indications where dendritic cell immunotherapy may offer clinical benefits.
Northwest Biotherapeutics has established partnerships with leading cancer centers and research institutions to support its global clinical development efforts. The company oversees manufacturing at its dedicated cellular processing facility in Maryland, ensuring consistent product quality and regulatory compliance. As part of its strategic growth, Northwest Biotherapeutics engages with international regulatory agencies to expand trial enrollment and accelerate potential approvals in Europe and North America.
The organization is guided by an experienced management team and scientific advisory board with deep expertise in oncology, immunology, and cell therapy commercialization. This leadership, combined with a patient-centric approach and a rigorous clinical development strategy, positions Northwest Biotherapeutics to advance its immunotherapy pipeline and potentially transform the standard of care for patients with challenging solid tumor cancers.
